NiveshIQ
Suven Life Sciences Ltd.
NiveshIQ has detected 5 active signals on SUVEN. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeAbout Suven Life Sciences Ltd.
Suven Life Sciences Limited is a clinical‑stage biopharmaceutical company focused on developing novel therapeutics for central nervous system disorders, targeting markets in India, the United States, Europe and beyond. Its flagship pipeline includes Masupirdine (SUVN‑502), a 5‑HT6 receptor antagonist for Alzheimer’s disease, and Samelisant (SUVN‑G3031), a histamine H3 receptor inverse agonist for narcolepsy and idiopathic hypersomnia. Additional candidates such as Ropanicant (SUVN‑911), Usmarapride (SUVN‑D4010) and Tenaclidine (SUVN‑I6107) address major depressive disorder, cognitive dysfunction and schizophrenia, respectively. Recent financials show revenue of ₹9 Cr but a net loss of ₹352 Cr, reflecting heavy R&D spending typical of early‑stage biotechs. The company’s competitive position
Financial Highlights
| Metric | FY26 |
|---|---|
| Revenue | ₹7.11 Cr +6.80% |
| EBITDA Margin | -3805.49% |
| Net Profit | |
| EPS | ₹-12.13 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Strategic Outlook
- Q4FY26 results: revenue ₹2 Cr, PAT ₹-46 Cr, EPS ₹-2.02, EBITDA margin -2885.5%. Growth context: revenue QoQ -45.9%, PAT QoQ -55.3%.
Patient volumes, occupancy, ARPOB/ARPO, case mix, and bed-capacity ramp-up remain the key forward drivers for the next 2...
FY26 (last completed FY): revenue ₹7 Cr, PAT ₹-276 Cr, EBITDA margin -3805.5%, EPS ₹-12.13. Year-on-year: revenue YoY +6...
Everything you unlock with a free account
Frequently Asked Questions
What AI signals does NiveshIQ provide for Suven Life Sciences Ltd.?
NiveshIQ detects active intelligence signals for Suven Life Sciences Ltd. (SUVEN) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Suven Life Sciences Ltd.?
Suven Life Sciences Ltd. operates in the Healthcare sector with a market capitalisation of ₹871,140.7L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.